Biontech Se ADR (BNTX)

$96.00 -0.73 (-0.75%)
Market Cap 21.64B
Revenue (ttm) 2.98B
Net Income (ttm) -719.92M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -24.18%
Debt to Equity Ratio 0.01
Volume 1,608,433
Avg Vol 879,664
Day's Range N/A - N/A
Shares Out 225.18M
Stochastic %K 27%
Beta 1.30
Analysts Strong Sell
Price Target $136.84

Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical tri...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 6131 9084
Fax: 49 6131 9084
Address:
An der Goldgrube 12, Mainz, Germany
hotzenplotz5
hotzenplotz5 Dec. 4 at 3:03 PM
$BNTX daily short
0 · Reply
El_Luz
El_Luz Dec. 4 at 11:44 AM
$BNTX It almost feels a bit like cheating to be able to peek at the outstanding results now, before everyone else gets to see them on December 6... https://airdrive.eventsair.com/eventsairsthcusprod/production-iaslc-public/394b88e8f88b422cb985e0bc379ba22b
1 · Reply
Robert321
Robert321 Dec. 4 at 11:35 AM
$BNTX BNTX demonstrates with gotistobart a medical breakthrough at ASCO December 7-9! Interim results show measurable superiority over the current standard, and the drug has received fast track approval from the FDA and in China. Let's go! Gotistobart beats chemotherapy with an HR of 0.46. !! https://airdrive.eventsair.com/eventsairsthcusprod/production-iaslc-public/394b88e8f88b422cb985e0bc379ba22b
1 · Reply
HedgeAlerts
HedgeAlerts Dec. 4 at 7:33 AM
Hedge Alert Live - Protect Your Portfolio Contract: $BNTX $95.00 Put · DEC 19, 2025 Exp Entry Price: $2.50 - $2.60 Exit Price Target: $5.00 Profit Margin: +100% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
finansbull88
finansbull88 Dec. 4 at 6:34 AM
$BNTX
0 · Reply
Robert321
Robert321 Dec. 3 at 9:49 PM
$BNTX JEFFERIES upgrades BioNTech to 'Buy' NEW YORK (dpa-AFX Analyser) - The Jefferies research firm has maintained its "Buy" rating for BioNTech with a price target of $151. The 12-month survival rate of patients with a specific type of non-small cell lung cancer treated with BioNTech's Gotistobart appears to be better than with current standard therapy, Akash Tewari wrote on Wednesday, citing published study data. /rob/mis/tih Publication of the original study: December 3, 2025 / 12:55 PM / Time zone not specified in the study Initial distribution of the original study: December 3, 2025 / 12:55 PM / Time zone
0 · Reply
taxplanr
taxplanr Dec. 3 at 4:09 PM
$BNTX $CVAC when does that ACIP meeting start?
0 · Reply
hotzenplotz5
hotzenplotz5 Dec. 3 at 3:55 PM
$BNTX short squeeze needed....
0 · Reply
finansbull88
finansbull88 Dec. 3 at 7:40 AM
$BNTX The company is an acquisition candidate with an upside of x10-20.
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Dec. 2 at 11:48 PM
💎 LiquidTheta® Live Actionable Trade Asset: $BNTX Contracts: $BNTX January 15, 2027 $100 Calls Scale in: $16.65- $20.35 Scale out: $64.75-$111.00 Profit Potential : 265% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
Latest News on BNTX
BioNTech Achieves Minimum Condition in CureVac Exchange Offer

Dec 3, 2025, 9:01 AM EST - 1 day ago

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

CVAC

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

Dec 1, 2025, 3:50 PM EST - 3 days ago

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

MRNA NVAX PFE

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

Dec 1, 2025, 12:35 PM EST - 3 days ago

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

MRNA NVAX PFE

BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration

Nov 26, 2025, 7:30 AM EST - 8 days ago

BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration

BioNTech SE (BNTX) Discusses Oncology Innovation Strategy, Combination Therapies and Personalized Cancer Immunotherapies Transcript

Nov 17, 2025, 6:17 PM EST - 16 days ago

BioNTech SE (BNTX) Discusses Oncology Innovation Strategy, Combination Therapies and Personalized Cancer Immunotherapies Transcript

Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up

Nov 13, 2025, 5:20 PM EST - 21 days ago

Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up

PFE

Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run

Nov 13, 2025, 11:10 AM EST - 21 days ago

Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run

PFE

BioNTech says collaboration with Pfizer remains unchanged

Nov 13, 2025, 8:17 AM EST - 21 days ago

BioNTech says collaboration with Pfizer remains unchanged

PFE

BioNTech Q3 Earnings: Plenty Of Cash And Pipeline Potential, But Still A Hold

Nov 3, 2025, 1:44 PM EST - 4 weeks ago

BioNTech Q3 Earnings: Plenty Of Cash And Pipeline Potential, But Still A Hold

BioNTech SE (BNTX) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 12:46 PM EST - 4 weeks ago

BioNTech SE (BNTX) Q3 2025 Earnings Call Transcript

BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership

Nov 3, 2025, 10:29 AM EST - 4 weeks ago

BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership

BMY

BioNTech lifts 2025 revenue guidance on BMS partnership payment

Nov 3, 2025, 6:47 AM EST - 4 weeks ago

BioNTech lifts 2025 revenue guidance on BMS partnership payment

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

Nov 3, 2025, 6:45 AM EST - 4 weeks ago

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

BioNTech to Host Innovation Series R&D Day on November 11, 2025

Oct 28, 2025, 7:45 AM EDT - 5 weeks ago

BioNTech to Host Innovation Series R&D Day on November 11, 2025

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025

Oct 27, 2025, 7:45 AM EDT - 5 weeks ago

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025

BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

Oct 22, 2025, 6:45 AM EDT - 6 weeks ago

BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

Moderna Vs BioNTech: Who's Winning The Post-COVID Race

Oct 18, 2025, 9:30 AM EDT - 6 weeks ago

Moderna Vs BioNTech: Who's Winning The Post-COVID Race

MRNA

Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead

Oct 8, 2025, 10:15 AM EDT - 2 months ago

Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead

CRSP

BioNTech SE, InstaDeep Ltd - Special Call

Oct 1, 2025, 6:52 PM EDT - 2 months ago

BioNTech SE, InstaDeep Ltd - Special Call

Why BioNTech Stock Jumped by Nearly 4% on Wednesday

Oct 1, 2025, 6:13 PM EDT - 2 months ago

Why BioNTech Stock Jumped by Nearly 4% on Wednesday

BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025

Sep 23, 2025, 6:45 AM EDT - 2 months ago

BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025

Why BioNTech Stock Bumped Higher Today

Sep 22, 2025, 6:45 PM EDT - 2 months ago

Why BioNTech Stock Bumped Higher Today

Mizuho's Jared Holz: There's not much value left in vaccine stocks

Sep 19, 2025, 11:40 AM EDT - 2 months ago

Mizuho's Jared Holz: There's not much value left in vaccine stocks

MRNA NVAX PFE

Why BioNTech Stock Sank by More Than 7% Today

Sep 12, 2025, 6:19 PM EDT - 2 months ago

Why BioNTech Stock Sank by More Than 7% Today

COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says

Sep 12, 2025, 1:37 PM EDT - 2 months ago

COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says

JNJ KVUE MRNA PFE

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy

Sep 8, 2025, 2:01 PM EDT - 3 months ago

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy

BMY

BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial

Sep 8, 2025, 11:05 AM EDT - 3 months ago

BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial

BMY

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

Sep 8, 2025, 11:00 AM EDT - 3 months ago

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

Pfizer, partner BioNTech say updated COVID shot shows better immune response

Sep 8, 2025, 7:02 AM EDT - 3 months ago

Pfizer, partner BioNTech say updated COVID shot shows better immune response

PFE

Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula

Sep 8, 2025, 6:45 AM EDT - 3 months ago

Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula

PFE

Why BioNTech Stock Crushed the Market Today

Sep 5, 2025, 4:41 PM EDT - 3 months ago

Why BioNTech Stock Crushed the Market Today

BioNTech, Duality score initial trial win with breast cancer precision drug

Sep 5, 2025, 5:13 AM EDT - 3 months ago

BioNTech, Duality score initial trial win with breast cancer precision drug

mRNA Biotechs - Long-Term Value Risks Abound

Aug 28, 2025, 6:20 AM EDT - 3 months ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY DHR GRAL ILMN IONS MRNA RGEN

Pfizer and BioNTech's COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

Aug 27, 2025, 12:50 PM EDT - 3 months ago

Pfizer and BioNTech's COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

PFE

CureVac settles patent dispute litigation with Pfizer and BioNTech

Aug 7, 2025, 9:00 PM EDT - 4 months ago

CureVac settles patent dispute litigation with Pfizer and BioNTech

CVAC PFE

These Analysts Revise Their Forecasts On BioNTech After Q2 Results

Aug 5, 2025, 1:36 PM EDT - 4 months ago

These Analysts Revise Their Forecasts On BioNTech After Q2 Results

BioNTech SE (BNTX) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 1:56 PM EDT - 4 months ago

BioNTech SE (BNTX) Q2 2025 Earnings Call Transcript

BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth

Aug 4, 2025, 10:32 AM EDT - 4 months ago

BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth

BioNTech Stock Rises as Drug Maker Beats Earnings Expectations.

Aug 4, 2025, 7:01 AM EDT - 4 months ago

BioNTech Stock Rises as Drug Maker Beats Earnings Expectations.

BioNTech's Q2 revenues double on higher COVID vaccine sales

Aug 4, 2025, 6:52 AM EDT - 4 months ago

BioNTech's Q2 revenues double on higher COVID vaccine sales

BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update

Aug 4, 2025, 6:45 AM EDT - 4 months ago

BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update

Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent

Aug 1, 2025, 4:51 PM EDT - 4 months ago

Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent

MRNA PFE

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Aug 1, 2025, 8:31 AM EDT - 4 months ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY AMGN ARGX AZN BAX

President Trump demands drugmakers slash prices within 60 days

Aug 1, 2025, 6:54 AM EDT - 4 months ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT ALNY AMGN ARGX AZN BAX

Pfizer, BioNTech lose UK appeal to overturn Moderna's COVID vaccine patent win

Aug 1, 2025, 5:59 AM EDT - 4 months ago

Pfizer, BioNTech lose UK appeal to overturn Moderna's COVID vaccine patent win

MRNA PFE

Pandemic darlings Moderna, BioNTech are now on two different paths

Jul 31, 2025, 7:00 AM EDT - 4 months ago

Pandemic darlings Moderna, BioNTech are now on two different paths

MRNA

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union

Jul 25, 2025, 2:30 AM EDT - 4 months ago

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union

Jul 25, 2025, 2:30 AM EDT - 4 months ago

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union

PFE

8MM Exanthema Market Report 2025-2034 | Rising Viral Infections and Diagnostic Innovations Across Major Markets Fueling Growth

Jul 23, 2025, 4:11 AM EDT - 4 months ago

8MM Exanthema Market Report 2025-2034 | Rising Viral Infections and Diagnostic Innovations Across Major Markets Fueling Growth

PFE

BioNTech to Report Second Quarter 2025 Financial Results and Corporate Update on August 4, 2025

Jul 21, 2025, 6:45 AM EDT - 4 months ago

BioNTech to Report Second Quarter 2025 Financial Results and Corporate Update on August 4, 2025

hotzenplotz5
hotzenplotz5 Dec. 4 at 3:03 PM
$BNTX daily short
0 · Reply
El_Luz
El_Luz Dec. 4 at 11:44 AM
$BNTX It almost feels a bit like cheating to be able to peek at the outstanding results now, before everyone else gets to see them on December 6... https://airdrive.eventsair.com/eventsairsthcusprod/production-iaslc-public/394b88e8f88b422cb985e0bc379ba22b
1 · Reply
Robert321
Robert321 Dec. 4 at 11:35 AM
$BNTX BNTX demonstrates with gotistobart a medical breakthrough at ASCO December 7-9! Interim results show measurable superiority over the current standard, and the drug has received fast track approval from the FDA and in China. Let's go! Gotistobart beats chemotherapy with an HR of 0.46. !! https://airdrive.eventsair.com/eventsairsthcusprod/production-iaslc-public/394b88e8f88b422cb985e0bc379ba22b
1 · Reply
HedgeAlerts
HedgeAlerts Dec. 4 at 7:33 AM
Hedge Alert Live - Protect Your Portfolio Contract: $BNTX $95.00 Put · DEC 19, 2025 Exp Entry Price: $2.50 - $2.60 Exit Price Target: $5.00 Profit Margin: +100% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
finansbull88
finansbull88 Dec. 4 at 6:34 AM
$BNTX
0 · Reply
Robert321
Robert321 Dec. 3 at 9:49 PM
$BNTX JEFFERIES upgrades BioNTech to 'Buy' NEW YORK (dpa-AFX Analyser) - The Jefferies research firm has maintained its "Buy" rating for BioNTech with a price target of $151. The 12-month survival rate of patients with a specific type of non-small cell lung cancer treated with BioNTech's Gotistobart appears to be better than with current standard therapy, Akash Tewari wrote on Wednesday, citing published study data. /rob/mis/tih Publication of the original study: December 3, 2025 / 12:55 PM / Time zone not specified in the study Initial distribution of the original study: December 3, 2025 / 12:55 PM / Time zone
0 · Reply
taxplanr
taxplanr Dec. 3 at 4:09 PM
$BNTX $CVAC when does that ACIP meeting start?
0 · Reply
hotzenplotz5
hotzenplotz5 Dec. 3 at 3:55 PM
$BNTX short squeeze needed....
0 · Reply
finansbull88
finansbull88 Dec. 3 at 7:40 AM
$BNTX The company is an acquisition candidate with an upside of x10-20.
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Dec. 2 at 11:48 PM
💎 LiquidTheta® Live Actionable Trade Asset: $BNTX Contracts: $BNTX January 15, 2027 $100 Calls Scale in: $16.65- $20.35 Scale out: $64.75-$111.00 Profit Potential : 265% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 2 at 10:18 PM
$BNTX Current Stock Price: $96.07 Contracts to trade: $95 BNTX Dec 19 2025 Call Entry: $3.90 Exit: $5.38 ROI: 38% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
hotzenplotz5
hotzenplotz5 Dec. 2 at 4:17 PM
$BNTX billions incoming and the Stock is going down, you US Investors are Kind of crazy
0 · Reply
hotzenplotz5
hotzenplotz5 Dec. 2 at 4:15 PM
$BNTX https://www.faz.net/aktuell/rhein-main/wirtschaft/biontech-investiert-milliarden-in-krebstherapie-accg-200264940.html?share=Whatsapp&premium=0x11e5e04bab662b3394a57d84aae11b879b4f07477892f40de2489305d597f9cd US people are Out of Control.
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 2 at 3:37 PM
$MRNA $BNTX $PFE $NVAX
0 · Reply
taxplanr
taxplanr Dec. 2 at 3:25 PM
VAERS When Restricted to US/Domestic Territories Reveals 19,480 Vaccine Deaths as of August 29, 2025 $BNTX $MRNA $PFE Several thousand within hours of taking the shots. VAERS is mainly used by doctors who have determined the vaccine caused a side effect or death after injection. Reports on the VAERS can be used to determine if a vaccine caused or contributed to an adverse event or illness because the doctor in the field has made the determination. CDC has all the doctor's information to verify the determination.
2 · Reply
taxplanr
taxplanr Dec. 2 at 3:02 PM
$BNTX $CVAC game of chicken with ACIP board meeting GLTA
0 · Reply
finansbull88
finansbull88 Dec. 2 at 12:41 PM
$BNTX PURE GOLD!
1 · Reply
Specialist001
Specialist001 Dec. 2 at 10:19 AM
$MRNA $BNTX IS MRNA NOT AS GOOD AS IT WAS HOPED? MODERNAL CANCELLED 3 VACCINES AFTER POOR TRIAL RESULTS
1 · Reply
El_Luz
El_Luz Dec. 2 at 9:49 AM
$BNTX BNTX could rebound today. Yesterday's negative headlines are all familiar issues and pose no new threat – above all, BNTX has a decisive advantage over its competitors: For babies under 1 year old, Biontech only used 3 micrograms, while Moderna used 25 micrograms. That’s almost as much as the 30 micrograms given to adults (Biontech). If a baby is sensitive and has side effects, 733% more is already a really big difference. $MRNA, $PFIZER.NSE
1 · Reply
finansbull88
finansbull88 Dec. 2 at 9:28 AM
$BNTX .Is BioNTech buying up Circio Holding now? The Circio share can be bought extremely cheaply on the Oslo Stock Exchange now. Check the results it is a game changer in Circular RNA https://www.thepharmanavigator.com/news/circio-unveils-next-generation-circular-rna-expression-platform
0 · Reply
taxplanr
taxplanr Dec. 2 at 3:32 AM
$BNTX $MRNA $PFE just another sharp shooter for the end of the week firing squad $CVAC https://justthenews.com/politics-policy/health/rfk-jr-appoints-former-acip-chairman-martin-kulldorff-senior-hhs-post?utm_source=mux&utm_medium=social-media&utm_campaign=social-media-autopost
0 · Reply
topstockalerts
topstockalerts Dec. 2 at 1:27 AM
Shares of Moderna and BioNTech fell on Monday, likely in response to a FDA official’s memo outlining a link between COVID-19 mRNA vaccines and myocarditis deaths in 10 children. Concern about that link, particularly relating to teenage boys and young men, has been a key argument against administering mRNA-based COVID vaccines in children. Vinay Prasad, the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, reportedly issued a memo to staff last week that said the regulator plans to acknowledge that 10 children died after getting the vaccine. (The memo was widely reported by media outlets and shared publicly by Adam Feuerstein, a biotechnology journalist.) $MRNA $BNTX $PFE
0 · Reply